Target intelligence / Profile preview

Cytokine receptor-like factor 2 (CRLF2) (CRLF2)

Target
CRLF2
Molecular classification
Receptor, Type I cytokine receptor, Cytokine receptor
01

Overview

Cytokine receptor-like factor 2 (CRLF2), also known as the thymic stromal lymphopoietin receptor (TSLPR), is a type I cytokine receptor subunit that plays a critical role in immune regulation and hematopoiesis. CRLF2 heterodimerizes with the interleukin-7 receptor alpha (IL-7Rα) chain to form a functional high-affinity receptor complex for the cytokine thymic stromal lymphopoietin (TSLP). Upon TSLP binding, the receptor complex activates downstream intracellular signaling cascades, primarily the JAK/STAT (specifically JAK2, STAT3, and STAT5) and PI3K/Akt/mTOR pathways, which promote cell survival, proliferation, and differentiation. Under physiological conditions, CRLF2 is expressed on dendritic cells, monocytes, and other hematopoietic cells, where it drives T helper type 2 (Th2) cell-mediated immune responses.\n\nIn pathological contexts, CRLF2 is heavily implicated in both inflammatory diseases and hematological malignancies. Overexpression or dysregulation of the TSLP/TSLPR axis is a key driver of allergic and inflammatory disorders, including severe asthma, chronic obstructive pulmonary disease (COPD), and chronic rhinosinusitis with nasal polyps (CRSwNP). Furthermore, genetic rearrangements of the CRLF2 gene (such as fusions with IGH or P2RY8) occur in approximately 50% of Philadelphia chromosome-like (Ph-like) B-cell acute lymphoblastic leukemia (B-ALL) and Down syndrome-associated ALL, leading to aberrant cell-surface overexpression of TSLPR and constitutive JAK/STAT activation. Consequently, CRLF2/TSLPR has emerged as a highly promising therapeutic target. Therapeutic strategies include monoclonal antibodies like verekitug that block TSLP binding to treat inflammatory diseases, as well as TSLPR-targeted chimeric antigen receptor (CAR) T-cell therapies (TSLPR-CART) and bispecific antibodies (such as 1B7/CD3) designed to selectively eliminate CRLF2-overexpressing leukemia cells.

Other names
TSLPRTSLP receptorThymic stromal lymphopoietin receptorThymic stromal lymphopoietin protein receptorCytokine receptor-like 2CRL2IL-XRCRLF2Y
02

Mechanism of action

Monoclonal antibodies (such as verekitug and RG-7258) act as receptor antagonists by binding to TSLPR/CRLF2, preventing TSLP ligand binding and subsequent activation of downstream JAK/STAT (specifically JAK2, STAT3, STAT5) and PI3K/Akt/mTOR pathways. Chimeric antigen receptor (CAR) T-cell therapies (such as TSLPR-CART) and bispecific antibodies (such as 1B7/CD3) target TSLPR-expressing cells to induce direct T-cell-mediated cytolysis of CRLF2-overexpressing leukemia cells.

03

Biological functions

Signal transductionCell proliferationImmune responseCell survivalHematopoiesisT helper type 2 (Th2) cell differentiation
04

Disease associations

CancerInflammationAutoimmune disease
05

Safety considerations

Cytokine release syndrome (CRS)Immune effector cell-associated neurotoxicity syndrome (ICANS)On-target, off-tumor toxicity due to expression on normal tissues (e.g., dendritic cells, monocytes, heart, skeletal muscle, kidney, liver)Antigen loss or downregulation leading to therapeutic resistance and leukemia relapseImmunosuppression or impaired response to pathogens
06

Interacting drugs

3 more in the full profile.

07

Biomarkers

CRLF2 overexpressionCRLF2 gene rearrangementIGH-CRLF2 translocationP2RY8-CRLF2 fusionJAK2 mutationSTAT5 phosphorylation (pSTAT5)Fractional exhaled nitric oxide (FeNO)Blood eosinophil count

Beyond the preview

Go deeper on Cytokine receptor-like factor 2 (CRLF2) (CRLF2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytokine receptor-like factor 2 (CRLF2) (CRLF2).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call